PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis

• R Tummala,
• B Huang,
• HI BRUNNER,
• C Lindholm,
• F Jones,
• M Ramaswamy,
• E Cody,
• P Devarajan,
• D Sinibaldi,
• J Knagenhjelm,
• T Qiu,
• PZ Brohawn,
• WI White

Affiliations

R Tummala

1University of Minnesota, Minneapolis, MN

B Huang

Abbott, Abbott Park, USA

HI BRUNNER

2Division of Rheumatology Pediatric, Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center (CCHMC) ~ Cincinnati, OH ~ United States of America

C Lindholm

Karolinska Institutet, Department of Public Health Sciences, Division of Social Medicine, Stockholm, Sweden

F Jones

1University of Manchester, Manchester, UK

M Ramaswamy

Department of Virology, Royal Free Hospital and Royal Free and University College Medical School, London, UK

E Cody

3Division of Pediatric Nephrology, Cincinnati Children’s Hospital Medical Center (CCHMC) ~ Cincinnati, OH ~ United States of America

P Devarajan

4Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center (CCHMC) ~ Cincinnati, OH ~ United States of America

D Sinibaldi

6Applied Analytics & AI, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca ~ Gaithersburg, MD ~ United States of America

J Knagenhjelm

8Biometrics, Late Respiratory & Immunology, Pharmaceuticals R&D, AstraZeneca ~ Gothenburg ~ Sweden

T Qiu

5Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center (CCHMC) ~ Cincinnati, OH ~ United States of America

PZ Brohawn

7Translational Science & Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca ~ Gaithersburg, MD ~ United States of America

WI White

11Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca ~ Gaithersburg, MD ~ United States of America